Trial · NCT03875144
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
NCT03875144, Phase 2, Suspended, Institut du Cancer de Montpellier - Val d'Aurelle
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Malignant Peritoneal Mesothelioma (MESOTIP). Trials, record NCT03875144. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03875144
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
- NCT number
- NCT03875144
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Conditions
- Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Interventions
- PIPAC, Cisplatin, Pemetrexed
- First posted
- 2019-03-14
- Last updated
- 2026-02-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | overall survival | from randomization of first patient until the database cut-off | The overall survival is defined as the time from the date of randomization to the date of death from any cause |
| Secondary | Response to treatment using PFS | week 10, week21,every 4 months during 2 years | Progression free survival (PFS) defined as the time from the date of randomization to the date of any progression or death. PFS will be described with median PFS, 1 and 2y-PFS rate |
| Secondary | Adverse event | during treatment | Safety according to CTCAE v5.0. Complications related to PIPAC will also be defined according to CTCAE v5.0 as recent publications in the field of peritoneal carcinomatosis suggest that this classification is more reliable when compared with the Clavien Dindo classification for the peritoneal carcinomatosis surgery |
| Secondary | Feasibility of compliance | Week 21 | Feasibility rate of compliance defined as the percentage of patients who received 6 cycles of systemic chemotherapy and 4 PIPAC (for experimental arm). |
| Secondary | Conversion to resectability | surgery | Conversion to resectability rate defined as the percentage of patients eligible for cytoreductive surgery and HIPEC at the end of the treatment out of the total number of patients. Patients are eligible for surgery if preservation of at least 1.5 m of small bowel and of at least 2 m of lower gastrointestinal tube is feasible in case of complete cytoreduction. |
| Secondary | Quality of life evaluation | baseline, week10, week21, FU every 4 months during 2 years | Quality of life EORTC QLQ-C30 questionnaires according to EORTC Guidelines |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03875144
GET https://conductscience.org/api/trials/v1/NCT03875144/registered